SDC2 and colorectal carcinoma: We then demonstrated that aberrant methylation status of SDC2 can be readily detected in DNA derived from the bodily fluids, such as serum and stool, of patients with CRC [20, 29], indicating its potential as a noninvasive molecular diagnostic biomarker for the early detection of CRC.